There have been a slew of trials in this area, 4 years after the SYMPLICITY - 3 debacle (covered on #NephJC here).
Is renal denervation ready for a comeback given the results of these three well done, sham controlled RCTs with 24 hour ambulatory BP as outcome? Given the importance of this topic and getting it right, we will discuss all three trials in a couple of weeks.
Our summary and some expert commentary will be up in the next few days - so watch this space. Join us for the chats June 26/27th!
As expected - the renal denervation attracted a lot of attention. Beje did a super job hosting both the chats. And Sarah Gleeson accomplished the difficult task of curating those tweets into a coherent narrative!
Check out the overall summary of all our renal denervation trial bonanza from 2018.
This is the summary of the RADIANCE SOLO trial, of renal denervation using an intravascular ultrasound, in patients not on medications.
This is the summary of the SPYRAL HTN-ON trial - of renal denervation in patients on 1-3 medications.
This is the summary of one of the three RDN trials we are discussing - SPYRAL HTN-OFF, which examined the effect of renal denervation in patients with mild hypertension, who were off medications.
Next Tuesday and Wednesday we will discuss three, yes, three trials of renal denervation. Is renal denervation ready to rise, phoenix-like, from the ashes of Symplicity-3?